Articlenpj aging2026
Epigenetic aging and cancer incidence in a German cohort of older adults.
Article in npj aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rising life expectancy and an aging population highlight the importance of cancer control. DNA methylation (DNAm)-based biological age (BA) may provide insights into aging, carcinogenesis, and cancer prevention and care. We estimated five BA metrics among 1916 participants aged 50-75 years at baseline in the German ESTHER cohort, with repeat BA measurements available for 894 participants after 8 years. Multivariable linear regression was used to assess associations between prior cancer and baseline BA, while Cox proportional hazards models and restricted cubic splines evaluated associations of BA levels and trajectories with subsequent cancer risk. A history of malignant tumors was associated with higher baseline PCHannum and PCGrimAge in fully adjusted models. Older BA levels were significantly associated with increased long-term cancer risk, with hazard ratios up to 1.67 (95% CI 1.25-2.24) per standard deviation (SD) increase in PCGrimAge. Except for PCGrimAge, BA trajectories showed monotonic, linear associations with cancer risk, corresponding to a 33% to 37% higher risk per SD increase in slopes of four BA matrices. Accelerated biological aging was consistently associated with increased overall cancer risk, highlighting the potential value of longitudinal BA measures for cancer risk assessment, prevention, and monitoring.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.